{"title_page": "Sutimlimab", "text_new": "{{one source|date=October 2018}}\n\n{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = xizu\n| target            = [[complement component 1s]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 2049079-64-1\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = GNWE7KJ995\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| UNII = \n| KEGG = D11530\n| synonyms = BIVV009\n}}\n\n'''Sutimlimab''' ([[International Nonproprietary Name|INN]];<ref name=WHOList118>{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 | journal = WHO Drug Information | volume = 31 | issue = 4 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | author-link = World Health Organization }}</ref> development code '''BIVV009''') is a monoclonal antibody that is being investigated for [[cold agglutinin disease]].\n\nThis drug is being developed by Bioverativ, a Sanofi Company. {{as of|2018}}, sutimlimab is undergoing [[Phase III]] trials.\n\nSutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. (<ref> {{cite journal | vauthors = Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S | title = C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro | journal = Journal of Immunology | volume = 202 | issue = 4 | pages = 1200\u20131209 | date = February 2019 | pmid = 30635392 | pmc = 6360260 | doi = 10.4049/jimmunol.1800998 }}</ref>) \n\n== References ==\n{{reflist}}\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "text_old": "{{one source|date=October 2018}}\n\n{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = xizu\n| target            = [[complement component 1s]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 2049079-64-1\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| UNII = \n| KEGG = D11530\n| synonyms = BIVV009\n}}\n\n'''Sutimlimab''' ([[International Nonproprietary Name|INN]];<ref name=WHOList118>{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 | journal = WHO Drug Information | volume = 31 | issue = 4 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | author-link = World Health Organization }}</ref> development code '''BIVV009''') is a monoclonal antibody that is being investigated for [[cold agglutinin disease]].\n\nThis drug is being developed by Bioverativ, a Sanofi Company. {{as of|2018}}, sutimlimab is undergoing [[Phase III]] trials.\n\nSutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. (<ref> {{cite journal | vauthors = Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S | title = C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro | journal = Journal of Immunology | volume = 202 | issue = 4 | pages = 1200\u20131209 | date = February 2019 | pmid = 30635392 | pmc = 6360260 | doi = 10.4049/jimmunol.1800998 }}</ref>) \n\n== References ==\n{{reflist}}\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Sutimlimab"}
